Jazz Pharmaceuticals Stock
Jazz Pharmaceuticals plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- CEO
- Renee D. Gala
- Employees
- 2,890
- Market cap
- $13.6 B
- IPO
- 01/06/2007
Jazz Pharmaceuticals plc operates in the healthcare / biotechnology sector and is headquartered in Ireland. The company focuses on the development, clinical trials, and commercialization of pharmaceuticals for the global market. Its product portfolio includes medications to treat narcolepsy such as Xywav, or therapies…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Jazz Pharmaceuticals stock: price history
1D
-2.0%
1W
-3.7%
1M
-13.7%
6M
+3.3%
YTD
+23.7%
1Y
+56.6%
2Y
+81.8%
5Y
+49.4%
10Y
+77.6%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~23% weaker price swings than usual
Jazz Pharmaceuticals stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Jazz Pharmaceuticals develops and markets specialty pharmaceutical products for the treatment of sleep disorders, epilepsy, and oncology. A substantial portion of revenue is generated by products such as Xywav and Epidiolex in the United States, while the remaining market is distributed across Europe and international regions. The company maintains research activities for a broad pipeline across various cancer types and neurological diseases. Additionally, partnerships with multiple partners exist for the development of new therapies.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Wide
- Moat type
- Network effects
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
Zymeworks Inc.Description
Werewolf Therapeutics, Inc.Description
ALX Oncology Holdings Inc.DescriptionAsk the agents about Jazz Pharmaceuticals
Analyst assessment of Jazz Pharmaceuticals
PRICE TARGET LOW
US$229.00
CONSENSUS
US$292.80
MEDIAN
US$300.00
PRICE TARGET HIGH
US$337.00
0
STRONG BUY
43
BUY
5
HOLD
0
SELL
0
STRONG SELL
48
TOTAL · Buy
As of: 08/10/2026
Jazz Pharmaceuticals stock metrics
P/E
13.83
P/B
2.77
EV/EBITDA
10.02
RETURN ON EQUITY
4.0%
NET MARGIN
16.0%
DEBT/EQUITY
0.92
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.1%
FLOAT SHARES
62,356,316
AVG. DAILY VOLUME (30D)
781,056
Insider transactions (SEC)
GALA RENEE D
COZADD BRUCE C
Patil Neena M
GALA RENEE D
Henderson Mary Elizabeth
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.0%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Jazz Pharmaceuticals stock
What does Jazz Pharmaceuticals do?
Jazz Pharmaceuticals plc is a company in the Healthcare sector, Biotechnology industry, headquartered in Ireland.
The CEO is Renee D. Gala, the company employs around 2,890 people.
The IPO was on 01/06/2007; the stock trades on NASDAQ under the ticker JAZZ.
What do analysts say about Jazz Pharmaceuticals stock?
48 analysts rate the stock, the consensus is Buy (as of 08/10/2026).
The average price target is US$292.80, ranging from US$229.00 to US$337.00, with a median of US$300.00.
This is an external assessment, not a statement by Market Jury.
When does Jazz Pharmaceuticals report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -23% stronger than usual.
Does Jazz Pharmaceuticals pay a dividend?
No, Jazz Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Jazz Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Jazz Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Jazz Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.